Tivic Health enters ATM equity facility up to $10M; appoints Lisa Wolf as interim CFO

Valion Bio, Inc.

Equity Distribution Agreement with Maxim Group for at-the-market sales of common stock up to $10M aggregate offering price; current baby shelf limit $1.44M.
Maxim receives 3.0% commission; Tivic reimburses up to $40K expenses plus $5K per bringdown.
Kimberly Bambach resigns as interim CFO effective Oct 1, 2024; remains advisor for strategic transactions.
Lisa Wolf appointed interim CFO effective Oct 1, 2024; paid $275/hour as non-employee consultant; has served Tivic since June 2022 via Murdock Martell.
Wolf brings 30 years experience, including CAO at Resonant (RESN) and CPA at Arthur Andersen.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Kimberly Bambach

interim Chief Financial Officer

VBIO · Valion Bio, Inc.

Effective: 2024-10-01
Successor: Lisa Wolf
Filed: September 13, 2024, 7:59 PM ET

On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.

Appointed (interim)

Lisa Wolf

interim Chief Financial Officer and Principal Financial and Principal Accounting Officer

VBIO · Valion Bio, Inc.

Effective: 2024-10-01
Filed: September 13, 2024, 7:59 PM ET

Effective October 1, 2024, Lisa Wolf has been appointed as the Company’s new interim Chief Financial Officer and Principal Financial and Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberly Bambach departed as interim Chief Financial Officer at Valion Bio, Inc..

Action: resignation
Role: interim Chief Financial Officer

Exact text from the filing

On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Wolf was appointed as interim Chief Financial Officer and Principal Financial and Principal Accounting Officer at Valion Bio, Inc..

Action: appointed
Role: interim Chief Financial Officer and Principal Financial and Principal Accounting Officer

Exact text from the filing

Effective October 1, 2024, Lisa Wolf has been appointed as the Company’s new interim Chief Financial Officer and Principal Financial and Principal Accounting Officer.

View on SEC.gov

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-106464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.